Copyright © 2019. Inderes Oy. All rights reserved.
User account


Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
1862 investors follow this company
The company is not covered. See all listed companies from here.
BUY 3.26 LOWEST 3.26 VOLUME 19 656
SELL 3.29 HIGHEST 3.34 VALUE 0,065 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Latest insider trading

Type: stock_exchange_release
  • Biohit Oyj will release its financial statements for 2019 on Wednesday 19[th] of February 2020 at 9:30 am.  

  • The Annual Report, which contains the Financial Statements for 2019 and the Report of the Board of Directors, will be published approximately during week 13.

  • Biohit Oyj's Annual General Meeting has been planned for Wednesday 22[th] of April 2020 at 5:00 pm. The Board of Directors will call the General Meeting at a later date.

Type: stock_exchange_release

Press release
14.10.2019 at 16.15 local time (EEST)

The Ministry of Health of the Russian Federation's recommendation for early detection of gastrointestinal diseases is published in the Journal of Gastroenterology, Hepatology, Coloproctology. This official recommendation, published by three members of the Russian Academy of Sciences representing the Russian Gastroenterology and Oncology Organizations, describes in detail the research and treatment practices that require early detection of gastrointestinal diseases throughout the Russian Federation (1).

Type: stock_exchange_release

Biohit Oyj Half Year Financial Report 14 August 2019 at 9:30 am local time (EET)


January-June 2019

Type: stock_exchange_release

Biohit Oyj Stock Exchange Release August 9th 2019 at 15.30 pm local time (EET)

Type: stock_exchange_release

Biohit Oyj Press release 26.6.2019 at 14.15 local time (EEST)

Biohit Colonview® quick test is now available with a control reagent. Biohit ColonView QT Control (Cat. No. 602390) is intended as a positive quality control for BIOHIT ColonView® (Cat. No. 602 250.02). The product is an in vitro diagnostic medical device and intended to be used by healthcare professionals only.

Type: stock_exchange_release

Biohit Oyj Stock Exchange Release June 12, 2019 at 13.15 a.m. (EEST)

A total number of 88,552 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 12 February 2019 and 31 May 2019. These shares have been entered into the Trade Register on June 12, 2019, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on NASDAQ Helsinki as of June 13, 2019 together with the existing B-shares.

Type: stock_exchange_release

Person subject to the notification requirement
Name: Söderström, Daniela
Position: Other senior manager
Issuer: Biohit Plc
Reference number: 74370089ATTSNBXJVT29_20190603065401_4            

Transaction date: 2019-05-29
Instrument type: SHARE
ISIN: FI0009005482
Nature of the transaction: SUBSCRIPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 25 000 Unit price: 2.2766 EUR

Type: stock_exchange_release

Press Release
20.5.2019 at 10.30 local time (EET)

May is devoted to increase the awareness of digestive diseases and their prevention. Colorectal cancer is one of the most common types of cancer among the Finnish people. Biohit Oyj and UEG (United European Gastroenterology) encourage to prevention of these cancers by testing the intestinal and gastric health and by paying attention to a healthy lifestyle. 

Type: stock_exchange_release

Biohit Oyj: Other information disclosed according to the rules of the Exchange April 25, 2019 at 9:30 am local time (EEST)

Biohit Oyj’s Board of Directors has in its meeting yesterday elected Mr Osmo Suovaniemi as the Chairman of the Board of Directors.

Additional information:

Type: stock_exchange_release

Biohit Oyj: Decisions of the Annual General Meeting April 24, 2019 at 7:30 pm local time (EET)

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday April 24, 2019 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2018.

Distribution of dividends


English translation unavailable for Biohit.